Transforming growth factor-beta receptor-associated protein 1 (TGFBRAP1, also known as TRAP-1) serves as a critical chaperone and scaffolding protein in the TGF-beta signaling cascade. By physically bridging TGF-beta receptor I (TGFBR1/ALK5) and downstream Smad proteins (Smad2/3), TGFBRAP1 acts as a key intracellular gatekeeper of TGF-beta-mediated transcription. This makes it an attractive, highly specific target for therapeutic intervention in oncology, tissue fibrosis, and immune evasion diseases where classical TGF-beta pathway inhibition is limited by systemic toxicity.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for TGFBRAP1 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | TGFBRAP1 Recombinant Protein High purity (>95%), Endotoxin Controlled, Sequence Verified. Ideal for biochemical binding assays. |
View TGFBRAP1 Products |
| Gene Delivery | TGFBRAP1 Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and signaling assays. |
View TGFBRAP1 Products |
| Benchmark Ab | Anti-TGFBRAP1 Antibody Recombinant sequence-verified antibody for Western Blot, IP, and cellular localization controls. |
View TGFBRAP1 Products |
| Validator | TGFBRAP1 siRNA Set For target knockdown verification and signaling pathway validation. |
View TGFBRAP1 Products |
| Related Target A | TGFBR1 Direct upstream kinase partner; essential for profiling receptor-scaffold interactions. |
View TGFBR1 Products |
| Related Target B | SMAD2 Downstream transcription factor recruited by TGFBRAP1; vital for pathway activation assays. |
View SMAD2 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Protein-Protein Interaction (PPI) screening | High-purity recombinant TGFBRAP1 with verified theoretical MW and native-like folding. |
| Cellular pathway modulation analysis | Lentiviral vectors optimized for robust cytoplasmic expression in target immune/tumor lines. |
| Lack of reliable control reagents | Sequence-verified benchmark antibodies and functional validation siRNA sets included. |
| False positives in binding assays | Endotoxin-controlled, mass spectrometry-verified protein batches to eliminate non-specific interference. |
Live TGFBRAP1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for TGFBRAP1 therapeutics is intensifying, with major players shifting focus from traditional systemic TGF-beta ligand traps or receptor kinase inhibitors to intracellular scaffolding modulators. Because systemic inhibition of TGF-beta receptors often leads to severe cardiotoxicity and skin lesions, targeting intracellular adaptors like TGFBRAP1 offers a safer, tissue-selective therapeutic window. As first-generation pathway inhibitors face clinical hurdles, the next wave of R&&D is targeting TGFBRAP1 using small molecule protein-protein interaction (PPI) disruptors and targeted protein degraders (PROTACs).
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (PPI) | Academic Institutes, Biotech Startups | Solid Tumors, Fibrotic Diseases | Disruption Assay (Need high-purity recombinant TGFBRAP1 & TGFBR1) |
| PROTAC / Degrader | Targeted Protein Degradation Pioneers | Pancreatic Cancer, Hepatic Fibrosis | Ubiquitination & Degradation Assay (Need Lentivirus for cell line engineering) |
| RNA Therapeutics (siRNA/ASO) | RNAi Therapeutics Specialists | Myocardial Fibrosis, Advanced Glioblastoma | Knockdown Validation (Need validated siRNA control sets) |